Fortis Healthcare Ltd

- The company’s net debt as of June 30, 2025, is INR 1,869 crores with a net debt-to-EBITDA ratio of 0.92x, up from 0.22x on June 30, 2024. - The increase in debt was primarily due to funds raised to part finance the acquisition of a 31.5% private equity stake in Agilus Diagnostics and acquisition of the Fortis brand and trademarks. - There is no explicit mention of any current or planned new fundraising through debt or equity in the provided transcript. - The management has highlighted a disciplined approach toward acquisitions and a cautious stance on future investments. - Any future fundraising, if undertaken, will be done in a transparent and arm’s length manner. No specific planned or ongoing debt/equity fundraising beyond mentioned acquisitions was disclosed.

- Fortis Healthcare currently has approximately 15 robotic machines across its network and plans to add 4 more this year. - Each da Vinci robotic machine costs around INR 12 crores, while orthopedic robots cost about INR 5 crores. - The company is investing in oncology setups, adding oncology services to hospitals where it is currently not available, expecting continued oncology growth of about 27-28% CAGR. - Brownfield expansions include adding about 450 beds in Mohali, 250 beds in Jalandhar, and 180 beds in Amritsar. - A new 200-bed facility is planned for Manesar, and capacity additions are planned at Noida (including a 60-bed addition), Faridabad, and other locations. - Fortis has acquired the SRL brand to strengthen its diagnostic business. - The company has entered into an operations and maintenance agreement for 700 beds at Gleneagles India, expanding its operational footprint and seeking operational synergies.

- Hospital revenue expected to grow with addition of ~900 beds in FY26; about 50% to be operationalized within the year. - Ramp-up of Manesar facility anticipated to reach EBITDA breakeven soon with increasing monthly revenue. - ARPOB (Average Revenue Per Occupied Bed) growth projected around 5-6%, driven by day care, OPD, and robotic surgeries. - Oncology revenue growing at ~27-28% CAGR; contribution currently about 17-20% of total hospital revenue. - Robotic surgeries showing 75% YoY growth; expected to grow at ~50% next year with addition of new robotic machines. - Diagnostics gross revenue grew 7.4% YoY; operating EBITDA margins expected around 22-23% for the year. - Diagnostics volume growth ~5% with revenue growth moving from high single-digit towards early double-digit within 6-8 quarters. - International business revenue grew 21% YoY and expected to continue positive trend. - Organic and inorganic diagnostic expansion expected regionally without restricting to specific geographies.

- Hospital business: Expecting 2% margin improvement over the year; strong first quarter and new brownfield capacity expansions could support this (Page 7, 16). - Diagnostics business: Margin guidance around 22%-23% for the full year; growth projected at high single digits (around 9%-10%) in next few quarters moving towards low double digits in 6-8 quarters (Pages 7, 16). - Revenue growth: Hospital revenues grew 18.6% YoY; Diagnostics net revenue grew 6.3% YoY with improving operating EBITDA (Page 3). - ARPOB growth in hospital business expected around 5%-6%, supported by increasing share of complex cases and robotic surgeries growing at 50%-75% YoY (Pages 4, 13, 14). - Addition of approx. 900 beds planned this year, with rapid ramp-up expected, contributing significantly to revenue in coming years (Pages 11, 14). - Overall expectation of continued positive trajectory in revenue and profitability leveraging network expansion and operational efficiencies (Pages 3, 5, 16).

The transcript does not provide explicit details on current or expected orderbook or pending orders for Fortis Healthcare Limited. However, relevant points on operational expansions and future plans include: - Acquisition of Shrimann Superspecialty Hospital in Jalandhar, Punjab, adding 228 beds with potential expansion to 450 beds. - Operation and maintenance agreement with Gleneagles India managing approx. 700 beds across 5 hospitals and a clinic. - Planned addition of 900 beds in the current year, including brownfield expansions and new facilities like Manesar. - Expectations of ramp-up in new beds leading to significant revenue growth next year. No specific figures or commentary on orderbook or pending orders were mentioned during the call.